We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

VivoGlo™ Caspase 3/7 Substrate (Z-DEVD-Aminoluciferin Sodium Salt)

P1781_VivoGlo--Caspase-3-3a7-Substrate_3

Firefly Luciferase Prosubstrate Recognized and Cleaved by Caspase-3 and -7

  • High-quality substrate eliminates potential interference in assays due to the presence of endotoxins
  • Available in multiple sizes to accommodate a variety of experimental settings

Size

Catalog number selected: P1781

$ 1,234.00
Your price:
Add to Cart
This product is discontinued
VivoGlo™ Caspase 3/7 Substrate (Z-DEVD-Aminoluciferin Sodium Salt)
50mg
$ 1,234.00
Your price: Log in
Change Configuration

VivoGlo™ Caspase-3/7 Substrate (Z-DEVD-Aminoluciferin, Sodium Salt) is a firefly luciferase prosubstrate containing the DEVD tetrapeptide sequence recognized by caspase-3 and -7. Upon activation of caspase-3 or -7, the DEVD peptide is cleaved, and the liberated aminoluciferin reacts with luciferase to generate measurable light. Cleavage has been shown in in cellulo and in vivo systems. For mice, activity of a related salt was demonstrated when 10mg of the substrate in 150μl of saline was injected intraperitoneally. Other references suggest that doses as low as 1.5mg per mouse (50mg/kg) can be used. We recommend conducting a preliminary dose-response study using no more than 500mg/kg.

VivoGlo™ Caspase-3/7 Substrate (Z-DEVD-Aminoluciferin, Sodium Salt) has a minimum solubility of 500mg/ml in PBS, and the resulting solution is stable for at least 3 days at room temperature. Injection is usually done via the intraperitoneal route, and imaging is generally started 10 minutes after injection. Product integrity is ensured by packaging most products in amber vials with septa as well as offering ease of dilution and use for imaging experiments. VivoGlo™ Caspase-3/7 Substrate is packaged with fine tolerances to minimize the need to weigh substrates.

References

  1. Liu, J.J. et al. (2005) Cancer Biol. Ther. 4(8), 885 92.
  2. Shah, K. et al. (2005) Mol. Ther. 11(6), 926 31.
  3. Kizaka-Kondoh, S. et al. (2009) Clin. Cancer Res. 15, 3433 41.
  4. Scabini, M. In vivo imaging of early stage apoptosis measuring real-time caspase-3 activation. Presentation at: 4th European Molecular Imaging Meeting; 2009 May 27 30, Barcelona, Spain.

Specifications

You are viewing: P1781 Change Configuration

SDS

Choose language:

Download SDSPDF (40 KB) – English (United States)

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Specifications

You are viewing: P1782 Change Configuration

SDS

Choose language:

Download SDSPDF (40 KB) – English (United States)

Certificate of Analysis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

Let's find the product that meets your needs.

Talk to a Scientist

scientist-uk-angus

Angus

UK